Sophia Genetics has secured agreements with two leading U.S. integrated health systems—one a nonprofit multi-region network and the other a top-10 health system laboratory—both of which analyze millions of genetic samples annually. These partnerships expand the firm’s footprint in key markets and underscore its ability to attract high-volume genomic collaborators.

Under the agreements, the two institutions will deploy SOPHiA DDM™ to conduct genomic testing for up to 60,000 patients annually across the West Coast and Midwest. They will utilize Enhanced Exome, which supports full-exome analysis of over 20,000 genes, directly integrated into their laboratory workflows.

Embedding AI-native analytics aims to accelerate diagnosis and reduce operational costs by streamlining sample processing and turnaround times. The collaboration also provides a scalable foundation for internal research and innovation initiatives, enabling deeper genomic insights and potential development of new tests.

This expansion reinforces Sophia Genetics’ mission to democratize data-driven medicine and bolsters its presence in the United States. Serving nearly one million cancer and rare disorder patients annually, the firm is positioned for further growth in AI-driven precision medicine.